Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: JAMA Intern Med. 2014 Dec;174(12):1964–1971. doi: 10.1001/jamainternmed.2014.5336

Figure 1.

Figure 1

Observed 10-year risk of ASCVD in the Women's Health Study compared to that predicted by the ACC/AHA pooled cohort equations in clinical risk groups: A) Unadjusted; B) Accounting for a 25% reduction in ASCVD due to statin use; C) Accounting for the intervention effect (25% reduction) as well as a doubling of risk in statin users due to confounding by indication; D) Accounting for the intervention effects (25% reduction) and confounding by indication (doubling of risk) due to both statin use and revascularization procedures.